Traci Kyes and Makis Sigalas bring extensive industry experience to their roles focused on growing ViroCell's business in the United States and Europe.
Team ViroCell will be attending the Cell and Gene Therapy Conference in Mesa October 10-12, 2023.
London and New York, October 4, 2023–(BUSINESS WIRE)–ViroCell Biologics (“ViroCell” or the “Company”), a specialized contract development and manufacturing organization (“CDMO”) for cell and gene therapy clinical trials, has appointed Traci Kyes as Vice President. announcedMakis Sigalas, vice president of business development (U.S.), has been appointed senior business development director (Europe). Traci and his Makis are focused on driving growth in the U.S. and Europe, respectively, and bring a wealth of business development expertise from their roles across his CMDO businesses focused on cell and gene therapy. Bringing it to his ViroCell.
Makis, who joins ViroCell to accelerate business growth across Europe, brings more than 25 years of biopharmaceutical experience contributing to the development of innovative biotechnology products and business success. Most recently, he served as Director of Business Development at Catalent Cell and Gene Therapy (“Catalent”, NYSE:CTLT), his CDMO specializing in advanced therapeutics. Prior to that, Makis worked as a Business Development Manager at Cell and Gene Therapy Catapult in the UK. In both roles, Makis focused on building and maintaining relationships with cell and gene therapy clients to ensure continued business growth. Makis is also a founding partner of Omnigen Biotechnologies, Greece's first licensed umbilical cord stem cell bank, and Theracell Advanced Biotechnology, a regenerative medicine company focused on developing advanced technologies for bone and soft tissue repair. Makis holds a PhD in Molecular Oncology from the University of Newcastle and a BSc in Biology from the University of Athens. She then pursued postdoctoral research at Harvard Medical School, developing new genetic diagnostic techniques for colon and breast cancer.
Traci has a proven track record of identifying and managing operational and commercial opportunities for life science CDMOs, which she will leverage to lead ViroCell's business growth in the United States. She joins from her position as global business development director for her team's Viral Vector Services at Thermo Fisher Scientific (NYSE: TMO), which provides the leading viral vector CDMO services for cell and gene therapies. Prior to this, Traci served as Director of Business Development and later Vice President of Commercial Operations at Arranta Bio, a biotechnology research CDMO that partners with companies to accelerate the development and commercialization of new therapeutics. Ta. Traci also previously worked as Director of Business Development at Brammer Bio, a maker of viral vectors for cell and gene therapy. Brammer Bio was acquired by Thermo Fisher in 2019 for $1.7 billion. Traci earned her Bachelor of Science in Biology from Duke University.
John W. Hadden II, CEO of ViroCell, commented: “We are excited to welcome Traci and Makis to the ViroCell business development team, significantly strengthening our capabilities and expanding our opportunities in two of our key markets. The operational and development expertise that Traci brings and the entrepreneurial experience of Makis will be invaluable in shaping ViroCell's future. .”
Traci Kyes, ViroCell's incoming vice president of business development (US), commented: “I am excited to join ViroCell as it embarks on its next phase of growth as a specialist CDMO in cell and gene therapy. I look forward to being integrated into the team and working with industry experts to deliver our exciting growth strategy .We will particularly focus on building our U.S. business.”
Makis Sigalas, incoming Senior Business Development Director (Europe) at ViroCell, added: “ViroCell is an innovation-driven CDMO that can positively impact patients around the world by supporting the development of cell and gene therapies with its experience and state-of-the-art facilities. There is an exciting cell and gene therapy ecosystem where our services could be useful.'' We are excited to join the members of Team ViroCell on this journey. ”
These appointments include Brian Collins, former Chief Financial Officer of Cell and Gene Therapy Catapult, becoming Chief Financial Officer (“CFO”) and John Dawson, former Chief Executive Officer of Cell and Gene Therapy Catapult. It is the latest in a series of significant additions to the team, following the recent announcement of . Officer of Oxford Biomedica (LSE: OXB) as Non-Executive Chairman (“CEO”). The ViroCell team will be attending the Regenerative Medicine Alliance Cell & Gene Meeting in Mesa, Carlsbad, California, USA, October 10-12, 2023. If you would like to book a meeting to learn more about ViroCell's unique service offerings, please contact us at firstname.lastname@example.org.
– that's all –
Note to editors:
ViroCell Biologics is an innovation-driven contract development and manufacturing organization (“CDMO”) dedicated to the design and GMP manufacturing of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams and founded to meet the global demand for precisely engineered viral vectors, ViroCell is the choice for companies developing cell and gene therapies. We aim to be a partner that can help you. The team leverages its extensive track record to help clients reduce risk and accelerate new cell and gene therapies through clinical development, making it a choice for companies and academic innovators in the field. Our mission is to be your partner. Initially focused on manufacturing lentiviruses, gammaretroviruses, and AAV vectors, ViroCell continues to grow by enabling clients to begin clinical trials on a scalable platform, reducing cost, time, and regulatory risk. Provide value.
ViroCell's state-of-the-art vector manufacturing facility is located at the Zayed Research Center (“ZCR”) at Great Ormond Street Children's Hospital (“GOSH”), and ViroCell is working with GOSH to meet the global demand for viral vectors. Masu. .
View source version on businesswire.com. https://www.businesswire.com/news/home/20231003331689/ja/
For more information about our company, please contact us below.
John W. Hadden II, CEO
For media inquiries, please contact us below.
Simon Conway / Victoria Foster Mitchell / Tim Stamper
+44 (0)20 3727 1000